Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Characteristics of LP-003 Injection in Participants With Wheat Allergy
Sponsor: Longbio Pharma (Suzhou) Co., Ltd.
Summary
This is a multicenter, randomized, open-label Phase II clinical study to evaluate the safety, efficacy, pharmacokinetic (PK), pharmacodynamic (PD) and immunogenicity profiles of LP-003 injection in participants with Wheat dependent exercise induced anaphylaxis. Its primary objective is to explore and preliminarily evaluate the efficacy of LP-003 Injection in the participants with Wheat dependent exercise induced anaphylaxis, as well as to investigate its safety, pharmacokinetic (PK), pharmacodynamic (PD) profiles, and immunogenicity.
Official title: A Multicenter, Randomized, Open-Label Phase II Clinical Trial to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Characteristics of LP-003 Injection in Participants With Wheat Allergy
Key Details
Gender
All
Age Range
12 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2026-09-04
Completion Date
2027-10-15
Last Updated
2026-09-11
Healthy Volunteers
No
Conditions
Interventions
LP-003 Injection
s.c. injection, Q8W
Locations (1)
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China